COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00509938
Recruitment Status : Completed
First Posted : August 1, 2007
Last Update Posted : October 17, 2008
Information provided by:

Brief Summary:
The safety and tolerability of hLF 1-11 has to be established first in HSCT recipients who are at risk of developing, but have not yet developed, infectious complications due to invasive fungal disease. These patients are different from healthy volunteers because they have received myeloablative treatment which not only arrests haematopoiesis resulting in neutropenia but also induces mucosal barrier injury both of which predispose to infections which typically occur during the week after transplant. It is therefore essential to know that hLF 1-11 is when given during neutropenia and mucosal barrier injury before infections ensue

Condition or disease Intervention/treatment Phase
Hematopoietic Stem Cell Transplantation Bacterial Infections and Mycoses Drug: human lactoferrin peptide 1-11 Phase 1 Phase 2

Detailed Description:


Human lactoferrin (hLF) is a glycoprotein containing 692 amino acids and found in the saliva, milk, tears, and other body fluids. Peptide representing the first cationic domain, i.e. a peptide comprising the first eleven residues of hLF (further referred to as hLF1-11) was significantly more effective than the full length hLF or the peptide representing the second cationic domain in killing a variety of bacteria in vivo. The mechanism of action comprises a number of independent factors. The classical way to explain the efficacy is the direct killing effect, which typically is observed in vitro at relatively high concentrations. The results of in vitro and in vivo experiments suggest that the mechanism of action is predominantly through the intermediary of cells and/or components of the host as opposed to a direct interaction with the pathogen.

The objective is to develop hLF1-11 as an effective and safe antibacterial and antifungal for the treatment of fungal and bacterial infections that develop during the neutropenia that results from myeloablative therapy to prepare for a haematopoietic stem cell transplant (HSCT) formerly referred to as bone marrow transplant. Rates of infection and related morbidity are high in this population making it an attractive target for testing clinically the proof-of-principle that hLF1-11 can provided effective treatment. Subsequently, hLF1-11 will be developed further as a systemic antifungal agent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Safety and Efficacy of Human Lactoferrin hLF1-11 for the Treatment of Infectious Complications Among Haematopoietic Stem Cell Transplant Recipients Part A: Clinical Study Protocol SC12: Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
Study Start Date : March 2006
Actual Primary Completion Date : November 2006
Actual Study Completion Date : November 2006

Arm Intervention/treatment
Experimental: 1
5mg hLF1-11, single dose iv
Drug: human lactoferrin peptide 1-11
Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.

Primary Outcome Measures :
  1. Safety and tolerability by recording the vital signs, clinical chemistry, local tolerability and adverse events during the study [ Time Frame: 28 Days ]

Secondary Outcome Measures :
  1. formation of antibodies anti-hLF 1-11 during the study. [ Time Frame: 28 Days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • admitted for an autologous HSCT after myeloablative therapy with high-dose melfalan
  • managed with a 4-lumen central venous catheter
  • BMI <30
  • able and willing to participate
  • has provided written informed consent
  • there is no medical reason for exclusion
  • has adequate renal function (creatinine <110 µmol/L (man); <90 µmol/L (woman))
  • has adequate liver function (ASAT <40 U; ALAT <45 U; bilirubin <10µmol/L)
  • has no known allergy to lactoferrin
  • has no history of hepatitis and is not HIV seropositive
  • if a woman, functionally post-menopausal

Exclusion Criteria:

  • A history of, or presence of, significant respiratory, cardiovascular, neurological, haematological, endocrine, gastrointestinal, hepatic or renal disease or other condition known to interfere with the absorption, distribution, metabolism or excretion of drugs (as judged clinically relevant by the investigator).
  • Participation in a study with a new chemical entity or new molecular entity 3 months before or participation in a study with a registered drug less than 5 times of the half life of the registered drug before entering the study.
  • A clinically relevant history of intolerance or hypersensitivity to the study drug, or its additives and excipients in the intravenous formulation.
  • Evidence of having serum hepatitis or carrying the hepatitis B surface antigen or Hepatitis C antibodies or being HIV positive.
  • Subjects, who in the opinion of the investigator should not, for reasons of safety, participate in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00509938

Layout table for location information
UMC St. Radboud
Nijmegen, Gelderland, Netherlands, 6500 HB
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: J.P. Donnelly, PhD UMC St. Radboud, Nijmegen, The Netherlands

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jacques Arend MD, VP Medical Development, AM-Pharma Identifier: NCT00509938    
Other Study ID Numbers: AMP 02-01
IS 044096
First Posted: August 1, 2007    Key Record Dates
Last Update Posted: October 17, 2008
Last Verified: October 2008
Keywords provided by AM-Pharma:
Additional relevant MeSH terms:
Layout table for MeSH terms
Bacterial Infections
Anti-Infective Agents